C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies

Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320)
11/2006
11/08/2006	EP1719528A2 Compositions and methods for treatment of angiogenesis in pathological lesions
11/08/2006	EP1718977A1 Protein phosphorylation in t-cell receptor signaling pathways
11/08/2006	EP1718976A1 Protein phosphorylation in anaplastic large cell lymphoma
11/08/2006	EP1718967A2 METHODS OF DETECTING Lp-PLA2 ACTIVITY
11/08/2006	EP1718767A2 Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
11/08/2006	EP1718760A1 Protein phosphorylation in c-src signaling pathways
11/08/2006	EP1718750A1 E. coli 0157:h7 c1 esterase inhibitor-binding protein stce and uses thereof
11/08/2006	EP1718749A1 Humanized antibody
11/08/2006	EP1718737A1 Cancerous disease modifying antibodies
11/08/2006	EP1718736A1 Cancerous disease modifying antibodies
11/08/2006	EP1718678A2 Anti-human tenascin monoclonal antibody
11/08/2006	EP1718677A2 Monovalent antibody fragments useful as therapeutics
11/08/2006	EP1718676A1 Anti-clusterin oligoclonal antibodies for diagnosis and prediction of the aggressiveness of tumours, diagnostic method and related kits
11/08/2006	EP1718675A2 A method of providing a purified, virus safe antibody preparation
11/08/2006	EP1718674A2 Membrane attack complexes associated with circulating immune complexes
11/08/2006	EP1718669A1 Identification of novel ige epitopes
11/08/2006	EP1718668A1 Antibody purification
11/08/2006	EP1718386A1 A process for the purification of antibodies
11/08/2006	EP1718335A2 Drug conjugates
11/08/2006	EP1718334A2 Methods of diagnosing and treating pre-eclampsia or eclampsia
11/08/2006	EP1718333A2 Methods of modulating cd200 and cd200r
11/08/2006	EP1718332A1 Method for inhibiting the transendothelial migration of cells such as leukocytes or tumor cells by a cd-81 binding subsance and uses thereof
11/08/2006	EP1718310A2 Methods and compositions for treating tumors and metastatic disease
11/08/2006	EP1636360A4 Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
11/08/2006	EP1265920B1 Angiogenesis-associated proteins, and nucleic acids encoding the same
11/08/2006	EP1237930B1 Chimeric amyloid beta peptides
11/08/2006	CN1860132A Inhibitors of extracellular hsp90
11/08/2006	CN1858065A Process for preparing chain Alexander algae specific antibody and use
11/08/2006	CN1858064A Chicken yoke antibody resisting Bengalese cobra venom and its preparation
11/08/2006	CN1283798C Polypeptides and polynucleotides from coagulase-negative staphylocoui
11/08/2006	CN1283793C Chemokine-like factor superfamily having skeletal muscle stimulating activity and immunoregulation function
11/08/2006	CN1283663C Antithemolytic streptococcus, staphylococcus and candida albicans lgY antibody and preparation thereof
11/08/2006	CN1283662C Antagonistic anti-hFAS ligand human antibodies and fragments thereof
11/08/2006	CN1283652C Isolated nucleic acid molecule encoding cancer associated antigen, antigen itself, and uses thereof
11/07/2006	US7132554 Synergistic mixture of an orally administered taxane compound and the epidermal growth factor receptor antibody, cetuximab; especially for treaing colorectal cancer, breast cancer, gastric cancer, ovarian cancer, non-small cell lung cancer and cancers of the head and neck.
11/07/2006	US7132513 Bifunctional chelating agent
11/07/2006	US7132512 Medicament for the treatment of chlamydial infection
11/07/2006	US7132511 Modified anti-EGFR antibodies with reduced immunogenicity
11/07/2006	US7132510 Chimeric protein comprising immunogenic domains for directed targeting of tumor cells; immunotherapy; antitumor agents
11/07/2006	US7132509 Colon specific gene and protein
11/07/2006	US7132508 Mammalian chemokine reagents
11/07/2006	US7132507 Nucleotide sequences coding polypeptide for use in the treatment of cancer
11/07/2006	US7132401 Beta-secretase substrates and uses thereof
11/07/2006	US7132399 Mammalian cell surface DNA receptor
11/07/2006	US7132396 Compositions which can be used for regulating the activity of parkin
11/07/2006	US7132281 Methods and host cells for producing human monoclonal antibodies to CTLA-4
11/07/2006	US7132264 nucleic acid molecule comprising nucleotide sequences, that code fro single chain proteins which are serine protease inhibitors, used for prophylaxis of emphysema, cirrhosis, hepatitis, blood disorders, tumors and tumor metastasis
11/07/2006	US7132260 Controlling calcium channel blockers; central nervous system disorders, gastrointestinal disorders, cardiovascular disorders, muscular disorders
11/07/2006	US7132255 drug screening for compounds that enhance or suppress killer T cell activity by contacting a population of killer T cells which express biliary glycoprotein with a compound that binds biliary glycoprotein and determining the cytotoxicity or proliferation of the killer T cells relative to a control
11/07/2006	US7132248 Uses of galanin GALR2 receptors
11/07/2006	US7132121 Inhibition of viral infection using antigen-binding proteins
11/07/2006	US7132107 For prophylaxis and therapy of prevention and pneumococcal infection
11/07/2006	US7132100 Palivizumab formulation comprising in aqueous carrier at least 40 mg/ml of palivizumab, or an antigen-binding fragment thereof and histidine, wherein formulation is free of surfactants and inorganic salts; for preventing or treating symptoms associated with a respiratory syncytial virus infection
11/07/2006	US7132099 Methods of modulating T lymphocyte costimulation with an antibody to an 8F4 polypeptide
11/07/2006	CA2454605C Immunoaffinity isolation of modified peptides from complex mixtures
11/07/2006	CA2226436C Generation of immune responses to prostate-specific antigen (psa)
11/07/2006	CA2128511C Monomeric and dimeric antibody-fragment fusion proteins
11/07/2006	CA2091967C Monoclonal anti-ganglioside antibody, its preparation and use as a tumor therapeutic agent
11/02/2006	WO2006116727A2 Compositions and methods for detection of sirolimus
11/02/2006	WO2006116657A2 Single-chain antibody with cleavable linker
11/02/2006	WO2006116269A2 Antibodies to myostatin
11/02/2006	WO2006116260A2 Modulation of antibody effector function by hinge domain engineering
11/02/2006	WO2006116246A2 Method of treating cd30 positive lymphomas
11/02/2006	WO2006116076A2 Tab molecules
11/02/2006	WO2006116001A2 Antibodies for the treatment of cancers
11/02/2006	WO2006115548A2 Subunit vaccine against west nile viral infection
11/02/2006	WO2006115026A1 Humanin receptor or humanin-like polypeptide receptor
11/02/2006	WO2006114788A1 Kinesin polypeptides, polynucleotides encoding same and compositions and methods of using same
11/02/2006	WO2006114704A2 P-cadherin antibodies
11/02/2006	WO2006114700A2 Method of producing human igg antibodies with enhanced effector functions
11/02/2006	WO2006114284A2 AGONISTIC ANTIBODIES THAT BIND TO THE LT-β-RECEPTOR AND THEREBY MODULATE ADIPOSITY-ASSOCIATED PHENOTYPES AS WELL AS THEIR USE IN THERAPY
11/02/2006	WO2006114115A1 Combination of antibodies and glucocorticoids for treating cancer
11/02/2006	WO2006092457A3 Method and vaccine strategies for potentiating the immune response to prions following vaccination, diagnostic kits and pharmaceutical compositions for the prophylaxis and treatment of spongiform encephalopathies
11/02/2006	WO2006088740A3 Methods and compositions for impairing multiplication of hiv-1
11/02/2006	WO2006088700A3 Human ring specific bnp antibodies
11/02/2006	WO2006086716A3 Donor lymphocyte infusion of activated t cells for the treatment of cancer
11/02/2006	WO2006074389A3 Four-helical bundle protein zsig99
11/02/2006	WO2006055809A3 Antibodies against vascular endothelial growth factor receptor-1
11/02/2006	WO2006050343A3 Monoclonal antibodies to the propeptide of candida albicans and methods of use
11/02/2006	WO2006012351B1 Markers for brain damage
11/02/2006	WO2005004793A9 Compositions and methods for treating coagulation related disorders
11/02/2006	WO2004032711A3 Diagnosis and monitoring of inflammation, ischemia and appendicitis
11/02/2006	WO2003072715A3 Gasp1: a follistatin domain containing protein
11/02/2006	US20060248605 Beta-amyloid peptide-binding proteins and polynucleotides encoding the same
11/02/2006	US20060248603 Novel fibrillin-like polypeptides
11/02/2006	US20060248602 Contacting polynucleotide with acetylthiourea, N,N-dimethylthioformamide, N,N'-diphenylthiourea, N-ethylthiourea, 2-imidazolidinethione, 4(6)-methyl-2-thiouracil, N-methylthiourea, phenylthio-carbamid, 6-phenyl-2-thiouracil, 6-propyl-2-thiouracil, tetramethylthiourea, thioacetamide, thioacetanilide
11/02/2006	US20060247425 Glycosylated immunoglobulin and immunoadhesin comprising the same
11/02/2006	US20060247424 Anti-idiotype antibody, method of constructing the anti-idiotype antibody, and method of preparing idiotype antibody using the anti-idiotype antibody
11/02/2006	US20060247421 Liver x receptor alpha splicing mutant protein, gene thereof and utilization of the same
11/02/2006	US20060247420 Immune cell recptor ligand and immune cell receptor
11/02/2006	US20060247199 Methods and products for manipulating uncoupling protein expression
11/02/2006	US20060247198 TGF-beta type receptor cDNAs encoded products and uses therefor
11/02/2006	US20060247191 Chimeric cytoplasmic signalling molecules
11/02/2006	US20060247176 Recombinant expression system for production of a peptide capable of inhibiting the protease activity of Botulinum toxin B or tetanus toxin which expression system comprises a nucleotide sequence encoding the peptide operably linked to a control sequence for effecting expression
11/02/2006	US20060247164 Meltrins
11/02/2006	US20060246587 Methods for transfecting T cells
11/02/2006	US20060246568 Cytidine deaminase
11/02/2006	US20060246550 Construction of antibody using mrl/lpr mouse
11/02/2006	US20060246545 Gene inactivated mutants with altered protein production
11/02/2006	US20060246542 System for antibody expression and assembly

1 ... 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 ... 1494